Humankind Investments LLC Buys 2,893 Shares of AbbVie Inc. $ABBV

Humankind Investments LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 19.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,084 shares of the company’s stock after purchasing an additional 2,893 shares during the quarter. AbbVie comprises about 0.8% of Humankind Investments LLC’s investment portfolio, making the stock its 18th largest holding. Humankind Investments LLC’s holdings in AbbVie were worth $3,357,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fullerton Fund Management Co Ltd. grew its position in shares of AbbVie by 8.5% during the 2nd quarter. Fullerton Fund Management Co Ltd. now owns 1,707 shares of the company’s stock worth $317,000 after buying an additional 134 shares during the period. Gallagher Fiduciary Advisors LLC boosted its stake in AbbVie by 4.1% during the 2nd quarter. Gallagher Fiduciary Advisors LLC now owns 5,251 shares of the company’s stock worth $975,000 after acquiring an additional 205 shares during the last quarter. Elevatus Welath Management grew its holdings in AbbVie by 37.4% during the second quarter. Elevatus Welath Management now owns 2,900 shares of the company’s stock valued at $538,000 after purchasing an additional 790 shares during the period. EP Wealth Advisors LLC increased its stake in AbbVie by 1.0% in the second quarter. EP Wealth Advisors LLC now owns 127,442 shares of the company’s stock valued at $23,656,000 after purchasing an additional 1,314 shares in the last quarter. Finally, Engineers Gate Manager LP raised its holdings in AbbVie by 299.9% in the second quarter. Engineers Gate Manager LP now owns 147,747 shares of the company’s stock worth $27,425,000 after purchasing an additional 110,802 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.2%

NYSE:ABBV opened at $223.45 on Friday. The company has a market cap of $394.92 billion, a P/E ratio of 169.28, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The business has a 50 day moving average price of $227.25 and a two-hundred day moving average price of $209.59. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research analyst reports. Morgan Stanley boosted their price target on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday. Bank of America boosted their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Evercore ISI raised their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their target price for the stock from $225.00 to $265.00 in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $244.55.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.